# A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants

> **NCT04851977** · PHASE1 · COMPLETED · sponsor: **Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** Respiratory Syncytial Vaccine
- **BIOLOGICAL:** Respiratory Syncytial Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04851977
- **Lead sponsor:** Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-16
- **Primary completion:** 2019-04-07
- **Final completion:** 2019-08-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04851977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04851977, "A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04851977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*